MedChemWatch
Monthly Newsletter July 2017

Joining Forces: The Chemical Biology–Medicinal Chemistry Continuum: A paper published in Cell Chemical Biology

There have been many discussions with EFMC of late about the importance of Chemical Biology and the synergies with Medicinal Chemistry.  We are pleased to highlight a publication inviting the two disciplines to join forces for the common good.  It features several distinguished EFMC luminaries.

The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs. Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery.

Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients. Advances in cancer biology and drug discovery highlight this potential.

Read the full paper here

A paper written by:

Alleyn T. Plowright (Sanofi-Aventis, Germany), Christian Ottmann (Eindhoven University of Technology, The Netherlands), Michelle Arkin (University of California, United States), Yves P. Auberson (Novartis, Switzerland), Henk Timmerman (VU University, The Netherlands) and Herbert Waldmann (Max-Planck-Institute of Molecular Physiology, Germany)

Still time to register! - EFMC-ASMC'17 - Vienna, Austria - August 27-31, 2017

The EFMC-ASMC Symposium programme, put together by Karin BRINER (Novartis, United States) and Erick M. CARREIRA (ETH Zurich, Switzerland), will again offer a unique combination of medicinal and synthetic organic chemistry! The programme will include recent advances in new synthetic methodologies, total synthesis, fluorination, bioisosteres and building blocks, chemical biology, medicinal chemistry, drug discovery and development, and feature case studies and first-time disclosures.  More than are 430 participants already registered.

Enjoy 27 invited speakers from industry and academia and 12 selected oral communications. Also, do not miss the 235 posters which will be presented during the two poster sessions.

With a very attractive registration fee, we really hope that young scientists, particularly graduate students and postdoctoral fellows, will join us in Vienna!

EFMC-YMCS 2017: Oral Communications are announced!

The programme of the 4th EFMC Young Medicinal Chemist Symposium will include 17 oral communications from promising young medicinal chemists. Out of the 17 oral communications, 13 of them will be given by prize winners from national young medicinal chemist meetings in Europe, and 4 of them have been selected from the 30+ submitted abstracts.

The Oral Communications are: 

  • A Novel Hydantoin-Based Series of Dpre1 Inhibitors in M.Tuberculosis: Hit-to-Lead Optimization and Biological Profiling
    Ms Olga BALABON (UNIVERSITY OF ANTWERP, Belgium) 

  • Design and Synthesis of Functionalized Monocyclic 3-Amino-1-Carboxymethyl-Beta-Lactams as Potential Inhibitors of Penicillin Binding Proteins of Resistant Bacteria
    Ms Lena DECUYPER (GHENT UNIVERSITY, Belgium)

  • Molecular Recognition and Activation Mechanisms of Bitter Taste Receptors
    Dr Antonella DI PIZIO (THE HEBREW UNIVERSITY OF JERUSALEM, Israel
  • Modular Assembly of Reversible Multivalent Targeting Drug Conjugates 
    Mr Fábio Miguel FIGUEIREDO SANTOS (IMED.ULISBOA, Portugal)

  • Target Elucidation of Novel Trypanosomatid Inhibitors
    Mr Andrew FRASER (UNIVERSITY OF ST ANDREWS, United Kingdom)

  • The Catalytic Mechanism of The Iron-dependent Sulfoxide Synthase EgtB 
    Dr Kristina GONCHARENKO (UNIVERSITY OF BASEL, Switzerland)

  • Bicyclic Constrained Peptides Targeting the EGF-EGFR Interaction 
    Mr Salvador GUARDIOLA (INSTITUTE FOR RESEARCH IN BIOMEDICINE, Barcelona, Spain)

  • Exploring Hit-Identification Strategies for Energy-Coupling Factor Transporters, A Novel Target for the Development of Antibiotics 
    Prof. Anna K. H. HIRSCH (HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND, Germany)

  • Development of Ligands for the Short-Chain Fatty Acid Receptor Ffa2 
    Mr Anders HOJGAARD HANSEN (UNIVERSITY OF SOUTHERN DENMARK, Denmark)

  • Development of Non-Covalent In Vivo Active Butyrylcholinesterase Inhibitors 
    Mr Urban KOSAK (UNIVERSITY OF LJUBLJANA, Slovenia)

  • Design, Synthesis and Biological Enaluation of New Artemisinin Hybrid Molecules 
    Mr Antonios S. LETIS (UNIVERSITY OF PATRAS, Greece)

  • Facing Non-Alcoholic Steatohepatitis with Multitarget Compounds
    Dr Daniel MERK (ETH ZÜRICH, Switzerland)

  • Fluorophore One-Atom-Controlled Recognition of DNA/RNA Secondary Structure
    Ms Tamara SMIDLEHNER (RUDER BOSKOVIC INSTITUTE, Croatia)

  • Discovery and Characterization of Novel Potent F508-Del Cftr Correctors
    Dr Federico SORANA (FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, Italy)

  • The Role of The Sulfonyl Group on The Conformational Preferences Of Bis-Aromatic Compounds ¬ 5-Ht6 Receptor Antagonists and Beyond 
    Dr Jakub STARON (INSTITUTE OF PHARMACOLOGY, Poland)

  • Discovery and Optimization of Novel Inhibitors for the Ether Lipid-Generating Enzyme AGPS as Anticancer Agents 
    Dr Sergio VALENTE (SAPIENZA UNIVERSITY OF ROME, Rome, Italy)

  • In Situ Ugi Four-Component Reaction for the Protein-Templated Identification of Inhibitors of Endothiapepsin 
    Mr M. Yagiz ÜNVER (UNIVERSITY OF GRONINGEN, The Netherlands)

The symposium programme will also include 2 keynote lectures from Dr Christoph BOSS (IDORSIA PHARMACEUTICALS, Switzerland) and Dr Peter NUSSBAUMER (LEAD DISCOVERY CENTER, Germany).

Registration is still open, and the deadline to submit abstract for poster presentation is July 13!  

This year again, valuable prizes will be delivered to the best Oral Communication & best Poster selected by a jury, and to the best Presentation - voted by the public. More information on the Prizes can be found here.

Click here to Register and Submit your Abstract

NEWS FROM THE KNCV

Chris de Graaf (Free University Amsterdam, The Netherlands) from the KNCV has recently published four papers on diabetes targets GCGR and GLP-1R in Nature.

The research was performed in a broader European Medicinal Chemistry context, in a collaboration between Europe, China and the United States via the GPCR Consortium: A public private partnership including a role for European pharma companies like Boehringer-Ingelheim, Novo Nordisk, Lundbeck, Sanofi, and other pharma.

The Four Nature papers describing the receptor structures involved in glucose metabolism hold great promise for finding new ways to treat diabetes.

Click here to read the article.

NEWS FROM THE BMCS

The Biological & Medicinal Chemistry Sector (BMCS) announces: the 2017 Malcolm Campbell Memorial Award; the nineteenth iteration of its flagship meeting the Cambridge Medicinal Chemistry Symposium (September 10-13, Churchill College, UK) and the eleventh running of its annual meeting for young med chemists, the Biological and Medicinal Chemistry Postgraduate Symposium (December 8, University of Cambridge – UK) and 

EDITORIAL: READ ALL ABOUT IT!

The Biological & Medicinal Chemistry Sector (BMCS) is an Interest Group driven by members.  BMCS members currently benefit from free access to one of the principal journals in Medicinal Chemistry for your personal use.  Please access the journal MedChemComm using your RSC membership number and password.

Please also read one of the most recent articles from the winners of the BMCS 2017 Malcolm Campbell Memorial Award.  The AstraZeneca team describe the structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M

Butterworth et al. Med. Chem. Commun., 2017, 8, 820–822. DOI: 10.1039/c7md90012k 

http://pubs.rsc.org/en/content/articlelanding/2017/md/c7md90012k/

 

The BMCS announces the latest instalments of two of its most popular meetings: 

19th Cambridge Medicinal Chemistry symposium

10th-13th September 2017, Churchill College, Cambridge, UK

The call for poster abstracts will close on 21st July

Website:  http://www.rsc.org/events/detail/23597/19th-rsc-sci-medicinal-chemistry-symposium  

Contributions from the whole field of medicinal chemistry are invited. Flash presentation sessions are planned for a selected number which will involve a two-minute presentation of poster highlights.  Please submit your abstracts early to avoid disappointment - spaces for the symposium are now limited (the committee can provide a decision on acceptance of poster abstract prior to registration if required).  Some student bursaries are also available. Applications are invited from PhD and post-doctoral students studying at European academic institutions, preferably members of the RSC, SCI or EFMC. Those submitting abstracts for poster presentation will be favoured.


11th Biological and Medicinal Chemistry Postgraduate Symposium

Friday 8th December 2017, Department of Chemistry, University of Cambridge, Cambridge

Registration now open – go to https://goo.gl/Azm5Kb

Closing date for abstract submission is 15th September 2017

The Biological and Medicinal Chemistry Sector (BMCS) of the RSC will be hosting its 11th postgraduate symposium for PhD students and postdoctoral workers researching in biological or medicinal chemistry and related areas. The event will be held in the Department of Chemistry at the University of Cambridge on Friday 8th December 2017. Researchers working in these areas are invited to participate. Registration will start at 9:00 am with talks beginning at 10:00 am. The day will consist of 11 oral presentations (8 student and 3 keynote) plus a Flash Poster section. Each 20 minute student talk will be followed by 10 minutes for questions

Throughout the day there will be keynote talks from industrial and academic chemists. A buffet lunch will be provided to accompany the poster session.  The BMCS judges will be awarding prizes to participants. There will be prizes of £300 for the best oral presentation and of £150 for the best poster and these will be celebrated at the end of the day

If you are interested in presenting your relevant PhD or post-doctoral work please submit a half-page abstract by 15th September 2017 in addition to registering. Those selected by the BMCS committee to give oral presentations will be notified by 3rd November. Travel expenses will be reimbursed to speakers 

This event is FREE but all attendees should register as soon as possible and no later than by Friday 1st December 2017

For queries and abstract submission contact Dave Alker at dave.alker@btinternet.com

Online registration form:  https://goo.gl/Azm5Kb

The latest edition of MedChemComm, the official journal of the EFMC, is available at:

MedChemComm

 

EFMC ORGANISED EVENTS

EFMC SPONSORED EVENTS

September 25-28, 2017
Kazan, Russia
3rd Russian Conference on Medicinal Chemistry

January 28 - February 1, 2018
St Anton, Austria
1st Alpine Conference on Medicinal and Synthetic Chemistry

EFMC SPONSORED SCHOOLS

September 17-22, 2017
Vienna, Austria
9th Summer School on Drug Design

September 18-22, 2017
Rimini, Italia
Summer School in Pharmaceutical Analysis (SSPA)

JOB PORTAL

15/08/2017
Medicina; Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom
Read more


04/08/2017
Postdoctoral position (applied research): pharmacology, medicinal chemistry, Lucas Meyer Cosmetics - IFF group: R&D, Paris or Toulouse, France
Read more


02/08/2017
Research and Innovation Manager IOF Drug Discovery, University of Antwerp: IOF consortium Antwerp Drug Discovery Network (ADDN), Antwerp, Belgium
Read more


20/04/2017
Medicinal / Synthetic Organic Chemists, Concept Life Sciences: Drug Discovery, Sandwich, Kent, United Kingdom
Read more

EFMC